Concerta

Phase 3Small molecule

Johnson & Johnson

Concerta is one of 95 small molecule programs targeting Cognition. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionActive, not recruiting

TreatmentRecruiting

TherapeuticsRecruiting

CognitionPreclinical

Active, not recruiting

TreatmentPhase 3

Recruiting

TherapeuticsPreclinical

Recruiting

Competition

Competitive Landscape

350 competitors in Treatment

#DrugCompanyPhaseTrials

Concerta

Johnson & Johnson

Phase 3

1 2

Biltricide

Bayer

Preclinical

4 3

Levulan

Sun Pharmaceutical Industries, Inc.

Preclinical

1 4

Emtriva

Gilead

Preclinical

1 5

Niclocide

Bayer

Preclinical

1 6

Minipress

Pfizer

Preclinical

1 7

Theo-Dur

Pfizer

Preclinical

1 8

Hivid

CConrado Roberto Hoffmann Filho

Preclinical

6 9

Clomid

Ferring

Preclinical

1 10

Aurlumyn

BBTG International Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Treatment

NCT05842330

Clinical

Trials by Indication[1]

Safety and Efficacy2 trials

Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD

Completed·NNoven Therapeutics·Phase 3·NCT00444574·282 enrolled

A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00475735·72 enrolled

Attention Deficit Hyperactivity Disorder2 trials

Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Terminated·PPurdue Pharma LP·Phase 4·NCT04507204·267 enrolled

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT00246207·32 enrolled

Children2 trials

Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD

Completed·NNoven Therapeutics·Phase 2·NCT00151970·128 enrolled

Efficacy of Concerta in Treating ADHD in Mothers of Children With ADHD

Completed·UUniversity of Maryland, College Park·Phase 4·NCT00318981·40 enrolled

Treatment1 trial

Benefits of ADHD Treatment in Detained People

Recruiting·SStéphanie Baggio·Phase 3·NCT05842330·150 enrolled

SMA1 trial

A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT01118702·30 enrolled

6 more indications

Therapeutics1 trial

Neurofeedback-Based Digital Therapeutics for the Diagnosis and Treatment of ADHD in Children.

Recruiting·—·N/A·NCT06369714·210 enrolled

Memory1 trial

Adderall XR Compared With Concerta in Treating Young Cancer Patients With Memory, Attention, and Depression

Terminated·UUniversity of South Florida·Phase 2·NCT00069927·12 enrolled

Cognition1 trial

Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome

Completed·UUniversity of Geneva, Switzerland·N/A·NCT04647500·45 enrolled

Biomarkers1 trial

Biomarkers of ADHD Treatment Response

Completed·—·Phase 1·NCT05650775·16 enrolled

Interaction1 trial

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

Completed· Takeda logo

Takeda·Phase 1·NCT00901576·38 enrolled

Unspecified1 trial

Concerta (Methylphenidate) -To-Generic Switch Study

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT02730572·1,464 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Concerta. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Concerta compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Concerta. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Concerta

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Safety and Efficacy2 trials

Attention Deficit Hyperactivity Disorder2 trials

Children2 trials

Treatment1 trial

SMA1 trial

Therapeutics1 trial

Memory1 trial

Cognition1 trial

Biomarkers1 trial

Interaction1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News